Surgical extraction of cardiac implantable electronic device leads based on a heart team approach

Background: As cardiac implantable electronic devices, such as pacemakers, cardioverter defibrillators, and car-diac resynchronization therapies, have become more popular, device extraction has become more frequent. At our institution, individual treatment strategies are discussed at a heart team meeting. Transvenous lead extrac-tion (TVLE) is a first-line treatment; however, surgical lead extraction (SLE) is sometimes selected as a primary choice to provide optimal treatment and maintain the medical safety policy. This study aimed to investigate the validity of this heart team decision-making.Methods: From 2013 to 2021, 384 consecutive patients underwent lead extraction at our institution.Results: SLE was proposed as the primary intervention for 21 patients who had high risk of bleeding, difficult TVLE conditions, large vegetations, and other concomitant cardiac diseases. Of the 363 TVLE patients, 10 patients re-quired surgical intervention; 5 had TVLE difficulty followed by SLE and 5 had excessive bleeding. SLE was per-formed in 26 patients, 19 of whom required valve surgery, and 8 required plication of the great veins. In 4 of the 17 hybrid procedures with SLE and TVLE, excessive bleeding occurred due to laceration of the superior vena cava and innominate vein. Operative mortality was not observed in SLE patients but was observed in 1 of the 4 TVLE patients who required emergent open-chest hemostasis. Conclusions: The heart team discussion was essential to provide optimal treatment and maintain medical safety policies for each patient. SLE should be selected for patients with high risk of TVLE or other cardiac complications such as tricuspid valve incompetence.(c) 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.